In this regard, we found that decreased expression of microglial CD40 and brain soluble CD40L expression by LISPRO treatment might help attenuate Aβ associated pathology, suggesting that disruption of CD40-CD40L signaling could also be involved in attenuation of Aβ pathology in Tg2576 and 3XTg-AD mouse models. Here, CD40 is linked to Alzheimer disease.